What question did this study set out to answer?

The study aims to examine health status and productivity outcomes in adults with type 1 diabetes experiencing severe hypoglycemic events and impaired awareness of hypoglycemia.

June 7, 2026

1365-P: Health Status and Productivity in Adults with Type 1 Diabetes Using Advanced Diabetes Technology with Recurrent Severe Hypoglycemic Events and Impaired Awareness of Hypoglycemia: A Multinational Survey

Key Points

The study aims to examine health status and productivity outcomes in adults with type 1 diabetes experiencing severe hypoglycemic events and impaired awareness of hypoglycemia.
Ongoing 12-month prospective online survey
Enrolled 137 adults with type 1 diabetes using continuous glucose monitoring and insulin pumps
Participants completed various health-related questionnaires including EQ-VAS, DPM, and WPAI.
Average health status score was 68.5, significantly lower than the US general population norm of 80.4 (p-value not specified).
Diabetes-specific productivity scores were 20% and 23% lower than US adults with diabetes for work and life productivity respectively (DPM scores of 66.9 and 52.5).
Generic work productivity loss was 2.2 times greater compared to the US general population (WPAI scores of 37% vs 17%).

Abstract

Introduction and Objective: Severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia (IAH) remain major challenges for some people with type 1 diabetes (T1D), despite using continuous glucose monitoring (CGM) and insulin pumps. This study describes health status and productivity outcomes among adults with T1D using CGM and insulin pumps with recurrent SHEs and IAH. Methods: This ongoing 12-month prospective online survey enrolled adults with T1D using CGM and insulin pumps who reported recurrent SHEs (≥2 in the past year) and IAH (Clarke score ≥4). Participants were recruited through patient advocacy groups from Canada, Germany, France, Italy, UK and US. Participants reported diabetes-related complications and completed the EuroQoL Visual Analogue Scale (EQ-VAS), Diabetes Productivity Measure (DPM), and Work Productivity and Activity Impairment (WPAI) questionnaires. Baseline results are compared against US T1D and general population norms for contextualization. Results: Participants (N=137) had a mean age of 49. 6 years (range: 20-75), 71. 5% were female, 65. 0% were from US, 59. 1% worked for pay, and mean T1D duration was 34 years (range: 5-72). Health status (EQ-VAS score: 68. 5, SD: 19. 8) was 15% lower compared to US general population norm (80. 4). Diabetes-specific work and life productivity (DPM scores: 66. 9 and 52. 5) were 20% and 23% lower compared to US adults with diabetes (83. 3 and 68. 5), respectively. Generic work productivity showed 2. 2 times greater work productivity loss compared to US general population norm (WPAI scores: 37% vs 17%). Conclusion: Despite using CGM and insulin pumps, adults with T1D and recurrent SHEs and IAH reported substantial burden, including sub-optimal health and productivity, highlighting continuing unmet needs. Disclosure A. Boateng-Kuffour: Employee; Current; Vertex Pharmaceuticals Incorporated. Q. Zhang: Employee; Current; Veloxis Pharmaceuticals, Inc. A. Albanese-O'Neill: Consultant; Current; Sanofi. Advisory Panel; Current; Roche Pharmaceuticals, Vertex Pharmaceuticals Incorporated. Research Support; Current; Abbott Diabetes. A. Bubeck: None. L. Green: Other - Sponsorship to my organization; Current; Abbott Diabetes, Vertex Pharmaceuticals Incorporated, Sanofi. B. Hauck: None. S. Heller: Consultant; Current; Novo Nordisk. Other - DSMC chair and member; Current; Eli Lilly and Company. Advisory Panel; Current; Zucara Therapeutics, Vertex Pharmaceuticals Incorporated. W. Polonsky: Consultant; Current; Vertex Pharmaceuticals Incorporated, Dexcom, Inc. , Abbott Diabetes. Research Support; Current; Abbott Diabetes, Dexcom, Inc. Consultant; Current; Lilly Diabetes, MannKind Corporation. Research Support; Current; Lilly Diabetes. Consultant; Current; Sanofi, Insulet Corporation. P. Senior: Consultant; Ended; Abbott. Consultant; Current; Dexcom, Inc. Consultant; Ended; GlaxoSmithKline plc. Research Support; Current; Eli Lilly and Company. Consultant; Current; Novo Nordisk, Sana Biotechnology Inc. , Sanofi, Vertex Pharmaceuticals Incorporated. Consultant; Ended; Ypsomed AG. J. Speight: Advisory Panel; Current; Vertex Pharmaceuticals Incorporated. Other - AU10k Sponsorship for PSAD 2026 conference, Geelong, Australia; Current; Sanofi. S. Tutton: Advisory Panel; Ended; Vertex Pharmaceuticals Incorporated. Other - Patient Advisory Group Participation in the T1D Multi-National PRO study; Current; Vertex Pharmaceuticals Incorporated. R. Ziegler: Advisory Panel; Current; Abbott Diabetes, Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Current; Novo Nordisk. Advisory Panel; Current; Sanofi. Speaker's Bureau; Current; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Current; Roche Diabetes Care. N. Ainsworth: Consultant; Current; Vertex Pharmaceuticals Incorporated. C. Abbott: Employee; Current; Vertex Pharmaceuticals. A. Martin: Consultant; Current; Vertex Pharmaceuticals Incorporated. N. Li: Employee; Current; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Current; Vertex Pharmaceuticals Incorporated. B. L. Barber: None.

Mark Helpful

Bookmark

Relay